- ￥1150 - 4190
- Solarbio
- 北京
- IP5120
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
PF-AKT400
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1004990-28-6
- 规格：
1mg/5mg/10mg
| 规格： | 1mg | 产品价格： | ￥1150.0 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ￥2890.0 |
| 规格： | 10mg | 产品价格： | ￥4190.0 |
PF-AKT400 是一种有效的, ATP 竞争性的选择性 Akt 抑制剂。
| 基本信息 | |
| CAS | No.1004990-28-6 |
| 英文名称 | PF-AKT400 |
| 别名 | AKTproteinkinaseinhibitor2-Acetamido-5-Nitrothiazole;N-(5-Nitrothiazol-2-yl)acetamide |
| 分子式 | C20H22F2N6O |
| 分子量 | 400.43 |
| 溶解性 | Soluble in DMSO ≥5mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| SMILES | CCC1=CNC2=C1C(=NC=N2)N3CC[C@@](C3)(CNC(=O)C4=C(C=C(C=C4)F)F)N |
| InChIKey | MOZRQQTUYAYCQT-FQEVSTJZSA-N |
| InChI | InChI=1S/C20H22F2N6O/c1-2-12-8-24-17-16(12)18(27-11-26-17)28-6-5-20(23，10-28)9-25-19(29)14-4-3-13(21)7-15(14)22/h3-4，7-8，11H，2，5-6，9-10，23H2，1H3，(H，25，29)(H，24，26，27)/t20-/m0/s1 |
| PubChem CID | 25061501 |
| 靶点 | Akt |
| 通路 | PI3K/Akt/mTOR |
| 背景说明 | PF-AKT400 是一种有效的, ATP 竞争性的选择性 Akt 抑制剂。 |
| 生物活性 | PF-AKT400 is a broadly selective， potent， ATP-competitive Akt inhibitor， displays 900-fold greater selectivity for PKBα (IC50=0.5 nM) than PKA (IC50=450 nM).[1-2] |
| IC50 | PKBα:0.5nM;PKA:450nM[1] |
| In Vitro | PF-AKT400(Compound 42)provides significantly enhanced selectivity for Akt relative to earlier leads such as spiroindoline 2. Free IC50 and EC50 values are estimated for phospho-S6 reduction(110 nM)and Akt hyperphosphorylation(216 nM)，respectively. These values corresponded well to the cellular IC50 for PF-AKT400 in U87 cells measuring p-GSK-3α(310 nM)[2]. |
| 细胞实验 | PF-AKT400 is subsequently evaluated for modulation of Akt in tumors and in multiple in vivo mouse models of antitumor efficacy. It is active in a PC3 prostate carcinoma xenograft experiment，with 75% TGI observed at 100 mg/kg b.i.d. dosing for 10 days. In a colorectal carcinoma(Colo205)xenograft study，PF-AKT400 produces 60% TGI at 150 mg/kg b.i.d. after 10 days. Most intriguingly，in combination with Rapamycin(10 mg/kg，ip)，75 mg/kg b.i.d.(10 days)of PF-AKT400 results in 98% TGI in an additional PC3 prostate carcinoma xenograft study compared to 56% TGI and 66% TGI with PF-AKT400 and Rapamycin as single agents. To define the in vivo potency of PF-AKT400(Compound 42)in the PC3 xenograft model，oral administration of 25，75，and 100 mg/kg PF-AKT400 is performed with blood and tumor sampling over time. Immunoblot analysis of detergent-soluble extracts derived from PC3 tumors shows a significant reduction of S6 phosphorylation，and hyperphosphorylation of Akt upon treatment at doses that produced significant tumor growth inhibition. Plasma drug concentrations peak rapidly after oral administration of doses between 25-100 mg/kg(Tmax=0.5 h). Peak PD responses of phospho-S6 and phospho-Akt are observed at approximately 2-4h and 1h post-administration of PF-AKT400，respectively. The time-course of PD marker response is well described by a PK/PD model at doses that ranged from no efficacy(25 mg/kg)to maximal efficacy(100 mg/kg)[2]. |
| 动物实验 | Studies to describe the PK/PD relationship for PF-AKT400 are performed in male SCID/Beige mice bearing subcutaneous PC3 prostate carcinoma xenografts. Once tumors reach about ~300mm3 in size，PF-AKT400 is formulated in 0.5% methylcellulose vehicle and administered orally to 3 mice per dose group. Plasma and tumors are harvested over time，tumor lysates prepared，and the levels of phospho S6 reduction and phospho Akt induction are evaluated by immunoblot.[1] |
| 激酶实验 | A fluorescence polarization IMAP type assay is used. An amount of 15 μL of diluted PF-AKT400(Compound 42)in DMSO is mixed with 60 μL of reaction buffer(10 mM Tris-HCl，pH 7.5，10 mM MgCl2，0.1 mM EGTA，0.01% Triton-X100，1 mM DTT). Then 5 μL of the compound/buffer mixture，10 μL of a solution containing 4 μM ATP and 40 nM fluorescent-labeled Crosstide(Tamara-labeled GRPRTSSFAEG peptide)，and 5 μL of Akt1 protein(lacking the pleckstrin homology(PH)domain，containing an Asp at position 473，and prephosphorylated at Thr 308)in reaction buffer are combined. After a 90 min incubation，IMAP beads are added and plates are read(lamp filter，544 nm; emission filter，615 nm). The same procedure can be applied to full length Akt1 to provide similar results. All IC50 values are the geometric mean of at least n=2 determinations[2]. |
| 数据来源文献 | [1]. Chen SF， et al. Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations. J Mol Model. 2013 Nov;19(11):5097-5112. [2]. Freeman-Cook KD， et al. Design of selective， ATP-competitive inhibitors of Akt. J Med Chem. 2010 Jun 24;53(12):4615-4622. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
_ChIP_method.html Chromatin IP Method, ChIP buffers, Notes on ChIP Method, Quantative PCR using 32P dCTP. Hahn Lab. ChIP Assay Protocol PDF - /attach/2008/2008-02-01/2B/2B6C4EA25F257424710A50E83CB2F380.pdf Formaldehyde cross-linking
在Western blot、IHC/ICC/IF、ELISA/FACS（表位）/Co-IP、ChIP等这些实验中，都需要用到抗体，但是抗体市场的庞杂带来了质量的参差不齐，抗体的不可靠性也会给科研带来巨大损失，包括时间和资源上的浪费。2006年耶鲁大学病理学家David Rimm研究了一项有效治疗黑色素瘤皮肤癌的指导方法，这项技术的基础是抗体——可以结合成为特殊生物学分子的Y形大蛋白，而且可以在样本中标志它们的存在。而当他准备好资金来将这种检测推广到临床时，他的团队从同一家公司订购的新的同一
2F+DwTquooTcizAj6Sh40arj1e+iWJ2ispgsbT801bWi9OaaVDQ0u7N9Rf22Q7je3ypEkT/aXtAx/4gHh20RbetchuWXizve3YY/3L0LGHHqt8Cva+97zf/vEfvyYb4imWXpTxLz8m4rvgjodswc3X26Xnn2o3LbjZPv/Fv5GGuGa33/ZzO2n2HD17NAEWeUXwmQh44uy32U+uutL+69e+6jjedfsddvSxx3m8xNNFQ67wipqQKHyESZ35
技术资料暂无技术资料 索取技术资料
IP5120 PF-AKT400 抑制剂/拮抗剂/激动剂 索莱宝
￥1150 - 4190
